How to Get Trulicity in Rhode Island

What Is Trulicity and Why Do Rhode Island Patients Seek It?

Dulaglutide (brand name Trulicity) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and for reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Eli Lilly markets it as a prefilled, single-use pen administered once weekly. Rhode Island has an adult obesity prevalence of approximately 30.2% according to 2023 CDC Behavioral Risk Factor Surveillance System data, and type 2 diabetes affects an estimated 9.4% of Rhode Island adults, making GLP-1 receptor agonists among the most requested drug classes in the state. [1]

The REWIND trial (N=9,901) published in The Lancet in 2019 demonstrated that dulaglutide 1.5 mg once weekly reduced the composite MACE endpoint (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) by 12% compared with placebo over a median follow-up of 5.4 years (HR 0.88; 95% CI 0.79, 0.99; P<0.026). [2] That cardiovascular outcome data, combined with the drug's once-weekly dosing convenience, explains the rising prescription volume in Rhode Island primary care and cardiology offices.

The FDA-approved label permits use starting at 0.75 mg subcutaneously once weekly, with optional titration to 1.5 mg after four weeks if additional glycemic control is needed. Further titration to 3 mg and then 4.5 mg is available for patients who tolerate the lower doses. [3]

Who Can Prescribe Trulicity in Rhode Island?

Any Rhode Island licensed prescriber with Schedule II, V DEA authority can write a Trulicity prescription, provided dulaglutide falls within their scope. That group includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Rhode Island grants NPs full practice authority under Rhode Island General Laws Section 5-34-49, meaning NPs do not require physician supervision to prescribe. PAs prescribe under a collaborative agreement with a physician but are fully authorized to initiate GLP-1 therapy. [4]

Telehealth prescribing is legal in Rhode Island. The Rhode Island Department of Health permits synchronous audio-video encounters as the basis for new prescriptions, including for chronic disease medications like dulaglutide. A prescriber who holds an active Rhode Island license (or a multistate compact license recognized by Rhode Island) can evaluate a patient via video, review relevant labs, and transmit the prescription electronically to any Rhode Island pharmacy. The prescriber does not need a separate telemedicine-specific license beyond their standard Rhode Island prescriber registration.

Patients who are already established with an out-of-state provider can ask that provider to apply for a Rhode Island telehealth license through the Rhode Island Health Professionals' Credentials Verification System, a process that typically takes four to six weeks. Alternatively, platforms like HealthRX that hold active Rhode Island prescriber credentials can initiate therapy immediately.

Step-by-Step: Getting a Trulicity Prescription in Rhode Island

Getting dulaglutide prescribed follows a predictable sequence regardless of whether the patient uses an in-person office or a telehealth platform.

Step 1. Schedule an appointment. Book either an in-person visit with an endocrinologist, primary care physician, or internal medicine specialist, or schedule a synchronous telehealth visit with a licensed Rhode Island prescriber. Telehealth appointments for GLP-1 initiation typically run 20 to 30 minutes.

Step 2. Complete required labs. Most prescribers in Rhode Island order a metabolic panel before initiating Trulicity. The standard pre-treatment panel includes fasting glucose, hemoglobin A1c (HbA1c), a comprehensive metabolic panel (CMP) to evaluate renal and hepatic function, a lipid panel, and a thyroid-stimulating hormone (TSH) level. Dulaglutide carries a boxed warning regarding thyroid C-cell tumors (observed in rodent studies); a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) is an absolute contraindication. [3]

Step 3. Review your cardiovascular and metabolic history. REWIND enrolled patients with a mean age of 66 years and HbA1c of 7.3%, roughly 31% of whom had no prior cardiovascular event. Prescribers use this baseline profile to assess appropriateness. Patients with eGFR <15 mL/min/1.73 m² should not use dulaglutide without specialist oversight, as renal safety data in severe renal impairment are limited.

Step 4. Discuss insurance or payment options. The prescriber's office or the telehealth platform will confirm your coverage and discuss prior authorization if you carry Medicaid or certain commercial plans.

Step 5. Receive an electronic prescription. Rhode Island law permits fully electronic prescribing for non-controlled substances. The prescription is transmitted directly to your pharmacy.

Step 6. Pick up or receive the medication. Trulicity requires refrigeration (36°F to 46°F / 2°C to 8°C) but may be kept at room temperature (no higher than 77°F) for up to 14 days if needed. Most Rhode Island retail pharmacies stock at least the 0.75 mg and 1.5 mg pens.

Lab Requirements Before Starting Trulicity in Rhode Island

Rhode Island prescribers generally follow the American Diabetes Association (ADA) Standards of Care in Diabetes, which specify HbA1c testing at initiation and then every three months until a target below 7% is reached for most non-pregnant adults. [5] The ADA Standards state: "For patients with diabetes, glycated hemoglobin testing should be performed at least twice yearly in patients who are meeting treatment goals and quarterly in patients whose therapy has changed or who are not meeting glycemic goals." [5]

The minimum pre-prescription labs most RI providers require are:

• HbA1c (within the past 90 days)
• Fasting plasma glucose or a recent glucose reading
• Serum creatinine and estimated glomerular filtration rate (eGFR)
• Alanine aminotransferase (ALT) as a hepatic screen
• Urine albumin-to-creatinine ratio (UACR) if diabetic nephropathy screening is due

Some endocrinologists also request fasting insulin and C-peptide levels to confirm residual beta-cell function, particularly if type 1 diabetes has not been excluded. Dulaglutide is not approved for type 1 diabetes.

Lipase levels are not routinely ordered pre-treatment but should be checked if the patient develops significant abdominal pain after starting therapy, given the labeling note about pancreatitis risk. [3]

Rhode Island Medicaid Prior Authorization for Trulicity

Rhode Island Medicaid (administered through Neighborhood Health Plan of Rhode Island, United Healthcare Community Plan, and other managed care organizations) covers Trulicity for type 2 diabetes with prior authorization. The documentation requirements follow a step-therapy protocol.

Standard prior authorization criteria across Rhode Island Medicaid MCOs typically include:

1. Confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
2. HbA1c at or above 7.0% at initiation
3. Trial and failure (or clinical contraindication to) at least one first-line agent, usually metformin 1 to 000 mg twice daily for a minimum of 90 days
4. Prescriber attestation that the medication is medically necessary
5. For the cardiovascular outcome indication: documentation of established ASCVD or multiple cardiovascular risk factors

The prior authorization approval period is typically 12 months, after which the prescriber must submit a renewal with updated labs showing continued benefit (defined by most plans as an HbA1c reduction of at least 0.5 percentage points or documentation of maintained glycemic control). [6]

Commercial plans in Rhode Island, including Blue Cross Blue Shield of Rhode Island and Aetna, have similar step-therapy requirements. Eli Lilly's Trulicity Savings Card can reduce out-of-pocket costs to as low as $25 per fill per month for commercially insured patients who qualify, though this offer is not valid for federal or state government insurance programs.

Telehealth Providers Prescribing Trulicity in Rhode Island

Rhode Island's telehealth infrastructure for GLP-1 prescribing has expanded considerably since the state made permanent its pandemic-era telehealth rules through the Rhode Island Telehealth Act (2022). The following framework describes how to evaluate any telehealth provider before starting Trulicity remotely.

Tier 1: Confirm licensure. Verify the prescriber holds an active Rhode Island license via the Rhode Island Department of Health License Lookup at health.ri.gov. Dulaglutide is a prescription-only drug; no telehealth platform may prescribe it without a licensed Rhode Island prescriber on staff.

Tier 2: Confirm the clinical protocol. A quality telehealth provider for Trulicity should collect the labs described above before prescribing, not after. Platforms that offer same-day prescriptions without reviewing an HbA1c should raise concern.

Tier 3: Confirm pharmacy integration. The platform should transmit the prescription to a licensed Rhode Island pharmacy (retail or mail-order) or to a licensed 503A compounding pharmacy if compounded dulaglutide is being considered. Ask whether the pharmacy is NABP-accredited.

Tier 4: Confirm follow-up scheduling. GLP-1 initiations without a four-to-eight-week follow-up visit to assess tolerability, adjust dosing, and review side effects fall below the standard of care described in ADA Standards of Care Section 9. [5]

HealthRX maintains active prescriber credentials in Rhode Island and follows this four-tier protocol for every GLP-1 initiation. A licensed Rhode Island prescriber reviews labs, conducts a synchronous video visit, and transmits the prescription the same day the visit is completed.

503A Compounding Pharmacies and Dulaglutide in Rhode Island

Rhode Island law allows 503A compounding pharmacies licensed by the Rhode Island Board of Pharmacy to prepare individualized patient-specific compounds, including dulaglutide formulations, when a valid prescription is presented and a documented clinical need exists. This matters because name-brand Trulicity can cost approximately $900 to $1,100 per pen (four pens per month) without insurance, while 503A-compounded dulaglutide may be substantially less expensive.

Several important distinctions apply. Compounded dulaglutide is not FDA-approved. It has not undergone the same sterility, potency, and bioequivalence testing as the commercial Trulicity pen. The FDA has not placed dulaglutide on the 503B outsourcing facility drug shortage list (unlike semaglutide during 2022 to 2024), meaning large-scale 503B compounding of dulaglutide is not currently authorized. Individual 503A pharmacies, however, can fill patient-specific prescriptions when a licensed prescriber provides one and when the pharmacy meets Rhode Island Board of Pharmacy USP 797 sterile compounding standards. [7]

Patients choosing compounded dulaglutide in Rhode Island should confirm the pharmacy holds an active Rhode Island Board of Pharmacy license, complies with USP <797> sterile compounding guidelines, and provides a Certificate of Analysis (CoA) from an independent third-party laboratory for each compounded batch.

Transferring a Trulicity Prescription to Rhode Island

Patients relocating to Rhode Island or spending extended time in the state can transfer an existing Trulicity prescription from an out-of-state pharmacy. Rhode Island pharmacy law permits prescription transfers for non-controlled substances between licensed pharmacies. The receiving pharmacist contacts the dispensing pharmacy, obtains the remaining authorized refills, and enters the prescription into the new system.

One practical limitation: if the original prescription was written by an out-of-state prescriber who lacks a Rhode Island telehealth license, and if refills are exhausted, the patient will need a Rhode Island-licensed prescriber to write a new prescription. Most telehealth platforms can complete that evaluation within 24 to 48 hours for established GLP-1 users with current labs on file.

Patients with active Eli Lilly Trulicity Savings Cards can continue using those cards at Rhode Island retail pharmacies. CVS, Walgreens, Rite Aid, and several independent pharmacies across Providence, Warwick, Cranston, and other Rhode Island cities stock Trulicity in both the 0.75 mg and 1.5 mg presentations. The 3 mg and 4.5 mg pens may require a 24-to-48-hour special order at some locations.

What to Expect After Starting Trulicity in Rhode Island

The most common early side effects of dulaglutide are gastrointestinal: nausea (reported in 12.4% of patients at 0.75 mg and 21.1% at 1.5 mg in key AWARD trials), diarrhea, vomiting, and decreased appetite. [3] These effects typically peak in the first four to eight weeks and diminish as the gut adapts.

Rhode Island prescribers generally advise patients to:

• Inject Trulicity on the same day each week (any time of day, with or without food)
• Rotate injection sites among the abdomen, thigh, and upper arm
• Store unused pens in the refrigerator and remove each pen 30 minutes before injection to reduce injection-site discomfort
• Contact their prescriber if they experience severe or persistent abdominal pain, which could indicate pancreatitis

HbA1c typically begins to fall within the first four to eight weeks of treatment. In AWARD-5 (N=1,098), patients on dulaglutide 1.5 mg achieved a mean HbA1c reduction of 1.1 percentage points from a baseline of 8.1% at 52 weeks versus 0.39 percentage points on sitagliptin (P<0.001). [8] A follow-up HbA1c at 12 weeks is a reasonable checkpoint to assess initial response before titrating dose.

Weight loss is a secondary benefit. The mean body weight reduction in REWIND was approximately 1.5 kg from baseline with dulaglutide 1.5 mg at 5.4 years, modest compared with semaglutide's 14.9% weight loss in STEP-1 (N=1,961) at 68 weeks [9], but clinically meaningful for patients whose primary goal is glycemic control and cardiovascular risk reduction.

Cost, Insurance, and Patient Assistance in Rhode Island

Out-of-pocket cost without insurance for a 28-day supply of Trulicity (4 pens) at Rhode Island retail pharmacies ranges from approximately $875 to $1,050 depending on the pharmacy and dose. Several cost-reduction pathways exist.

Eli Lilly Insulin Value Program / Trulicity Savings Card: Commercially insured patients may pay as low as $25 per fill per month. Patients must not be using a federal or state government insurance program to qualify.

LillyCares Foundation: Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may qualify for free medication. Applications are processed through LillyAnswers.com.

Rhode Island Medicaid: As described above, covered with prior authorization for eligible patients meeting diagnostic and step-therapy criteria.

340B Program: Federally Qualified Health Centers (FQHCs) in Rhode Island, including Thundermist Health Center and Providence Community Health Centers, participate in the 340B drug pricing program. Eligible patients seen at these sites may access Trulicity at significantly reduced acquisition cost.

The Rhode Island Office of the Health Insurance Commissioner (OHIC) also maintains a prescription drug affordability resource list at ohic.ri.gov that includes GLP-1 cost-assistance contacts updated quarterly.